COMMUNIQUÉS West-GlobeNewswire

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
17/12/2025
On track for initial clinical data in mid-2026 Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering [...]
Singlera Genomics announces research collaboration with the University of Pittsburgh to advance pancreatic cancer early detection
17/12/2025
LA JOLLA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with their partner Breakthrough Genomics, a leader [...]
Transparency Notification from Shareholders
17/12/2025
Ghent, Belgium, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders PRESS RELEASE REGULATED INFORMATION 17 December 2025, 6:00 pm CET Ghent, Belgium – 17 December 2025 – Sequana Medical NV ( [...]
DeLorean AI Releases New Cardiovascular AI White Paper Showing Predictive AI Can Prevent Heart Failure and Cut Costs by Up to $350,000 Per Patient
17/12/2025
Clinically validated platform delivers predictive precision, empowering clinicians with real-time visibility to reduce preventable complications and improve patient outcomes PALM BEACH, Fla., Dec. 17, 2025 (GLOBE [...]
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
17/12/2025
No Shareholder Action Required at This Time BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and [...]
BioNTX Celebrates 2025 Rising Stars Driving North Texas’ Life Science Innovation
17/12/2025
Plano, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- As 2025 comes to a close, BioNTX reflects on a year of innovation, growth, and achievement across North Texas’ life science ecosystem, highlighted by the accomplishments [...]
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today [...]
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global, commercial stage, integrated [...]
Avalyn to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today [...]
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive [...]
Alignment Healthcare to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. [...]
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
17/12/2025
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient [...]
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
17/12/2025
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis [...]
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
17/12/2025
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye [...]
TadHealth Awarded San Diego County Office of Education Contract; School Districts to Begin CYBHI Billing in January 2026
17/12/2025
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth , a leading provider of school-based mental health technology, has been selected by the San Diego County Office of Education (SDCOE) to deliver a county- [...]
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
17/12/2025
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in an [...]
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
17/12/2025
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
17/12/2025
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were [...]
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
17/12/2025
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies BOSTON [...]

Pages